Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
Story summaryBEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.